My Account | Shopping Cart | Contact  
Trilink Biotech Logo

Oligonucleotides | mRNA & Long RNA | Nucleotides | CleanCap® | CleanTag® | CleanAmp® | Custom Chemistry | cGMP

OligoBuilder® | Nucleotides List | Stocked mRNA List | DNA Synthesis Reagents List | CleanAmp™ Products List

You are at: All > Nucleotides > Nucleotides by Structural Class > Sugar Modified Nucleoside Triphosphates



Extinction Coefficient: 9,100 Lmol-1cm-1 at 271 nm
Molecular Weight: 485.2 g/mol (free acid)
Molecular Formula: C9H15N3O13P3F (free acid)
Salt Form: Lithium
Purity Specification: ≥95% by AX-HPLC
Typically Shipped at 100 mM in H2O.
1 µmole: 10 µL
5 µmole: 50 µL
10 µmole: 100 µL

Certificate(s) of Analysis

2'-Fluoro NTPs are being utilized in an increasing number of applications in research and new drug development. 2'-Fluoro-dCTP is incorporated in both DNA and RNA constructs to improve in vivo stability. Both 2' Fluoro dC and dU are used in the design and synthesis of aptamers, antagomirs and siRNA, because they impart increased target affinity and resistance to endonuclease degradation, while reducing immune response.

A key technique utilized in aptamer development using 2'-Fluoro-dCTP is SELEX (Systematic Evolution of Ligands by Exponential Enrichment). The SELEX process allows for the simultaneous screening of 1 x 1015 different oligonucleotides against a target of interest, such as a protein. The main goal of SELEX is to identify a small subset of aptamers from the original library that bind to the target of interest. Learn more in the technical article: An Overview of the SELEX Process.

"TriLink offers not just better pricing but specialized services at large scale and functional, quality 2’-Fluoro-dCTP and 2’-Fluoro-dUTP. TriLink’s technical customer support was knowledgeable and gave me confidence about the products."

Sriramchandra Mangipudi Bioengineer
University of Washington, Seattle

Email a Friend
Product Inquiry
Ready To Order?

Please select a size :
   1 µmole ($53.00)
   5 µmoles ($146.00)
   10 µmoles ($265.00)
   5 x 10 µmoles ($1,137.00)
   10 x 10 µmoles ($1,390.00)


Related Products :

Related Categories :

Dupont DM, Thuesen CK, Bøtkjær KA, Behrens MA, Dam K, Sørensen HP, Pedersen JS, Ploug M, Jensen JK, Andreasen PA.Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites.PLoS One. 2015 Mar 20
Dupont DM, Larsen N, Jensen JK, Andreasen PA, Kjems J.Characterisation of aptamer-target interactions by branched selection and high-throughput sequencing of SELEX pools.Nucleic Acids Res. 2015 Jul 10
Johnsson P, Ackley A, Vidarsdottir L, Lui WO, Corcoran M, Grandér D, Morris KV. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells. Nat Struct Mol Biol. 2013 Feb 24. doi: 10.1038/nsmb.2516.
Thiel KW, et. al. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res. 2012 Mar 30. doi: 10.1093/nar/gks294
Lauridsen LH, Rothnagel JA, Veedu RN. Enzymatic recognition of 2'-modified ribonucleoside 5'-triphosphates: towards the evolution of versatile aptamers. Chembiochem. 2012 Jan 2;13(1):19-25.
Bompiani KM, Monroe DM, Church FC, Sullenger BA. A high affinity, antidote-controllable prothrombin and thrombin-binding rna aptamer inhibits thrombin generation and thrombin activity. J Thromb Haemost. 2012 Mar 2. doi: 10.1111/j.1538-7836.2012.04679.x.
Thiel WH, Bair T, Peek AS, Liu X, Dassie J, Stockdale KR, Behlke MA, Miller FJ Jr, Giangrande PH. Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS One. 2012;7(9):e43836.
Botkjaer KA, et. al. Targeting Tumour Cell Invasion And Dissemination In Vivo By An Aptamer That Inhibits Urokinase-Type Plasminogen Activator Through A Novel Multi-Functional Mechanism. Mol Cancer Res. 2012 Oct 4. doi: 10.1158/1541-7786.MCR-12-0349.
Green NM, Moody KS, Debatis M, Marshak-Rothstein A. Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands. J Biol Chem. 2012 Sep 27. doi: 10.1074/jbc.M112.383000jbc.M112.383000.
Cozens C, Pinheiro VB, Vaisman A, Woodgate R, Holliger P. A short adaptive path from DNA to RNA polymerases. Proc Natl Acad Sci U S A. 2012 May 22;109(21):8067-72.
Reif R, Haque F, Guo P. Fluorogenic RNA Nanoparticles for Monitoring RNA Folding and Degradation in Real Time in Living Cells. Nucleic Acid Ther. 2012 Oct 31. doi:10.1089/nat.2012.0380.
Liu J, Guo S, Cinier M, Shlyakhtenko LS, Shu Y, Chen C, Shen G, Guo P. Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. (2011) ACS Nano. 5(1):237-46.
Nicol, C., Bunka, D.H.J., Blair, G.E., Stonehouse, N.J. Effects of single nucleotide changes on the binding and activity of RNA aptamers to human papillomavirus 16 E7 oncoprotein (2011) Biomedical and Biophysical Research Communications, 405: 417-421.
Kanwar JR, Roy K, Kanwar RK. Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol. 2011 Dec;46(6):459-77.
Shu D, Shu Y, Haque F, Abdelmawla S, Guo P. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. (2011) Nature Nanotechnology, doi: 10.1038/nnano.2011.105. [Epub ahead of print]
Joubert MK, Kinsley N, Capovilla A, Sewell BT, Jaffer MA, Khati M. A modeled structure of an aptamer-gp120 complex provides insight into the mechanism of HIV-1 neutralization. (2010) Biochemistry, (49)(28): 5880-5890.
Prakasha Gowda AS, Polizzi JM, Eckert KA, Spratt TE. Incorporation of gemcitabine and cytarabine into DNA by DNA polymerase beta and ligase III/XRCC1. (2010) Biochemistry, (49)(23): 4833-4840.
Madsen JB, Dupont DM, Andersen TB, et al. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1. (2010) Biochemistry, (49)(19): 4103-4115.
Brown JA, Fiala KA, Fowler JD, Sherrer SM, Newmister SA, Duym WW, Suo Z. A novel mechanism of sugar selection utilized by a human X-family DNA polymerase. (2010) J Mol Biol. 15;395(2):282-90.
Brown JA, Fowler JD, Suo Z. Kinetic basis of nucleotide selection employed by a protein template-dependent DNA polymerase. (2010) Biochemistry, (49)(26): 5504-5510
McNamara J, et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice, The Journal of Clinical Investigation.
Du M, et al. Water soluble RNA based antagonist of AMPA receptors, Neuropharmacology.
Rhie A, et al. Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. (2003) J. Biol. Chem., 278: 39697-705.
Tahiri-Alaoui A, et al. High affinity nucleic acid aptamers for streptavidin incorporated into bi-specific capture ligands. (2002) Nucleic Acids Res., 30(10): e45.
Capodici J, Kariko K, Weissman D. Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. (2002) J Immunol., 169(9): 5196-201.
Rusconi C, et al. RNA aptamers as reversible antagonists of coagulation factor Ixa. (2002) Nature, 419: 30-34.
Sun LQ, Cairns MJ, Saravolac EG, Baker A, Gerlach WL. Catalytic nucleic acids: From lab to application. (2000) Pharmacological Reviews, 52: 325-347.
Jayasena SD. Aptamers: An emerging class of molecules that rival antibodies in diagnostics. (1999) Clinical Chemistry, 45(9): 1628-1650.
Ono T, Scalf M, Smith LM. 2'-Fluoro modified nucleic acids: polymerase-directed synthesis, properties and stability to analysis by matrix-assisted laser desorption/ionization mass spectrometry. (1997) Nucleic Acids Res., 25(22): 4581-8.
Ono T, Scalf M, Smith LM. 2'-Fluoro modified nucleic acids: polymerase-directed synthesis, properties and stability to analysis by matrix-assisted laser desorption/ionization mass spectrometry. Nucleic Acids Res. 1997 Nov 15;25(22):4581-8.



  Twitter Twitter Facebook Facebook Linked In Linked In RSS RSS Google RSS  
© 2019 TriLink BioTechnologies, LLC | All Rights Reserved